SEC Form SC 13G/A filed by Design Therapeutics Inc. (Amendment)
$DSGN
Biotechnology: Pharmaceutical Preparations
Health Care
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/7/2024 | $6.00 → $12.00 | Neutral → Overweight | Piper Sandler |
| 11/14/2023 | $42.00 → $6.00 | Overweight → Neutral | Piper Sandler |
| 8/15/2023 | $19.00 → $6.00 | Outperform → Neutral | Wedbush |
| 8/15/2023 | $23.00 → $7.00 | Outperform → Sector Perform | RBC Capital Mkts |
| 8/15/2023 | $6.00 | Outperform → Market Perform | SVB Securities |
| 5/4/2023 | $6.00 | Sell → Neutral | Goldman |
| 6/10/2022 | $21.00 | Outperform | Wedbush |
| 5/2/2022 | $30.00 | Outperform | RBC Capital Mkts |
SC 13D/A - Design Therapeutics, Inc. (0001807120) (Subject)
SC 13G/A - Design Therapeutics, Inc. (0001807120) (Subject)
SC 13G/A - Design Therapeutics, Inc. (0001807120) (Subject)
S-8 - Design Therapeutics, Inc. (0001807120) (Filer)
10-K - Design Therapeutics, Inc. (0001807120) (Filer)
8-K - Design Therapeutics, Inc. (0001807120) (Filer)
4 - Design Therapeutics, Inc. (0001807120) (Issuer)
4 - Design Therapeutics, Inc. (0001807120) (Issuer)
4 - Design Therapeutics, Inc. (0001807120) (Issuer)
3 - Design Therapeutics, Inc. (0001807120) (Issuer)
4 - Design Therapeutics, Inc. (0001807120) (Issuer)
4 - Design Therapeutics, Inc. (0001807120) (Issuer)
Piper Sandler upgraded Design Therapeutics from Neutral to Overweight and set a new price target of $12.00 from $6.00 previously
Piper Sandler downgraded Design Therapeutics from Overweight to Neutral and set a new price target of $6.00 from $42.00 previously
Wedbush downgraded Design Therapeutics from Outperform to Neutral and set a new price target of $6.00 from $19.00 previously
New Drug Product for Friedreich Ataxia (FA) DT-216P2 with Favorable Nonclinical Pharmacokinetic and Injection Site Safety Profile; Complete GLP Studies by Year-end 2024 to Start Patient Trials in 2025 IND Cleared for DT-168 for Treatment of Fuchs Endothelial Corneal Dystrophy (FECD) with Phase 1 Development to Start in 2024; Observational Study Underway to Confirm Patient Characteristics and Evaluate Potential Endpoints New Program Unveiled for Huntington's Disease (HD) Targeting Reduction of Mutant Huntingtin with a GeneTAC™ Small Molecule Cash and Securities of $281.8 Million at Year-end 2023 Support Five-Year Operating Runway and Advancement of Up to Four Progra
CARLSBAD, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today announced that the company will host a conference call and live webcast on Tuesday, March 19, 2024, at 4:30 p.m. ET to discuss its fourth quarter and full year 2023 financial results and provide a comprehensive portfolio update. The event will be webcast live under the "Events" section of the Investors page of www.designtx.com and can also be accessed here. A replay of the webcast will be archived on the Design website for 30 days. Dial-in information for conference participants may be obtained by regi
DT-216 Resulted in a Significant Increase in FXN mRNA Levels in Skeletal Muscle of FA Patients Treatment Generally Well-Tolerated; Injection Site Reactions Attributable to Current Formulation Composition Design Plans to Proceed with an Improved DT-216 Formulation and Initiate a Multiple Dose Phase 1 Clinical Study in the Second Half of 2024 Conference Call and Webcast to be Held Today at 4:30pm ET CARLSBAD, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today reported initial results from the company's Phase 1 multiple-ascending dose (MAD) clinical
Initiated Phase 1 Single Ascending Dose Trial of DT-216P2 in Healthy Volunteers; Friedreich Ataxia (FA) Patient Dosing to Begin in mid-2025 Dosing Complete in DT-168 Phase 1 Healthy Volunteer Trial, with Data on Track for the First Half of 2025; Enrollment Target Achieved in Fuchs Endothelial Corneal Dystrophy (FECD) Observational Study Selection of Development Candidate for Myotonic Dystrophy Type-1 (DM1) Expected in 2025 Well-Capitalized with Cash and Securities of $245.5 Million to Fund Operations Through Up to Four Potential Clinical Proof-of-Concept Data Sets CARLSBAD, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a clinical-stage biotechnolog
CARLSBAD, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat during Leerink's Global Healthcare Conference on Monday, March 10, 2025, at 1:40 p.m. ET in Miami. A live webcast of the fireside chat will be available here and in the investors section of the company's website at www.designtx.com. The webcast will be archived for at least 30 days following the presentation. About Design TherapeuticsDesign Therapeutics is a clinical-stage biotechnology company developing a new class of therap
CARLSBAD, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in the following upcoming investor conferences: 2024 Jefferies London Healthcare ConferencePresentation: Tuesday, November 19, 2024, at 10:00 a.m. GMTLocation: London, UK Piper Sandler 36th Annual Healthcare ConferenceFireside Chat: Tuesday, December 3, 2024, at 11:30 a.m. ETLocation: New York, NY Live webcasts of the presentations will be available here and in the investors section of the company's website at www.designtx.com. The webcasts will
Phase 1 Trial of DT-216, a Novel FA GeneTAC™ Molecule, in Patients with Friedreich Ataxia On Track to Begin Soon Preclinical Data Supporting Development of Novel GeneTAC™ Small Molecules for the Treatment of Fuchs Endothelial Corneal Dystrophy (FECD) to be Presented at ARVO 2022 Well-Capitalized with $384.1 Million in Cash and Investments at the End of 2021 to Support Upcoming Milestones CARLSBAD, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a biotechnology company developing treatments for degenerative genetic disorders, today announced pipeline and business progress and reported fourth quarter and full year 2021 financial results. "This is an e
CARLSBAD, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a biotechnology company developing treatments for degenerative genetic disorders, today announced that Jae Kim, M.D., FACC, has been appointed as chief medical officer. Dr. Kim will play a pivotal role in leading clinical strategy and development, including the company's first clinical trial planned to begin in the first half of 2022. "I am thrilled to welcome Jae to Design, particularly as we prepare to embark on the important transition to a clinical stage company and initiation of our Phase 1 clinical trial in patients with Friedreich ataxia," said João Siffert, M.D., president and chief execut
Preclinical Data Support Initiation of Clinical Development of Lead GeneTAC Program for Friedreich Ataxia in the First Half of 2022 Leadership Team Strengthened with Appointment of Elizabeth Gordon, Ph.D., as Senior Vice President of Regulatory Affairs CARLSBAD, Calif., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a biotechnology company developing treatments for degenerative genetic disorders, today reported recent progress with its portfolio of novel small molecule gene targeted chimeras (GeneTACsTM), as well as business highlights and second quarter 2021 financial results. "So far in 2021, we've made substantial progress as a company, highlighted by the